Relmada Therapeutics Inc (NASDAQ:RLMD) reported its fourth quarter and full-year 2025 financial results, delivering a significant earnings miss against analyst expectations. The clinical-stage biotech's stock experienced a decline in after-hours trading following the announcement, reflecting investor focus on the widening net loss.
Earnings Versus Estimates
The company's financials for the quarter ended December 31, 2025, highlighted the ongoing costs of advancing its clinical pipeline in the absence of commercial revenue.
- Revenue: Reported revenue was $0.0 million, meeting the consensus estimate of $0.0 million. This aligns with expectations for a pre-revenue biotech firm.
- Earnings Per Share (EPS): The reported non-GAAP EPS was a loss of $0.27. This fell substantially short of the analyst estimate for a loss of $0.1428, representing a negative earnings surprise of approximately 89%.
The wider-than-expected loss underscores the substantial investment required for clinical development. For the full year 2025, Relmada reported a net loss of $86.3 million, or $2.35 per share, compared to a net loss of $117.5 million, or $3.69 per share, for the full year 2024.
Market Reaction and Recent Performance
The immediate market reaction to the earnings release was negative. In after-hours trading following the announcement, the stock declined by 2.72%. This short-term move suggests investors were disappointed by the magnitude of the quarterly loss relative to forecasts.
Looking at a broader timeframe, the stock's performance has been volatile but positive over the past month, potentially driven by anticipation around pipeline updates rather than financials.
- Last Month Performance: +52.21%
- Last Two Weeks Performance: +30.19%
- Last Week Performance: -1.74%
The sharp monthly gain indicates significant investor interest, which the quarterly earnings results and associated costs appear to have tempered in the near term.
Business Update Highlights
Beyond the financial figures, the corporate update contained several key pipeline developments that form the core of the company's investment thesis.
- NDV-01 for Bladder Cancer: The company highlighted positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC), demonstrating a 95% complete response rate at any time. This asset, acquired from Novartis, represents a potential near-term catalyst and diversification beyond the central nervous system (CNS) portfolio.
- REL-1017 (esmethadone) for Depression: Relmada continues to advance its lead CNS program, REL-1017, a novel NMDA receptor antagonist for major depressive disorder (MDD). The update noted ongoing analysis from previous studies and preparations for future clinical development.
- Financial Position: The company reported cash, cash equivalents, and short-term investments of $109.6 million as of December 31, 2025. Management believes this runway is sufficient to fund operating expenses and capital expenditure requirements into the second half of 2027, providing a clear timeline for key data readouts.
Looking Ahead
The press release did not provide specific quantitative financial guidance for the coming quarters. The company's near-term trajectory will be judged almost entirely on clinical milestones rather than revenue generation. Investors will be closely monitoring the development path for NDV-01 in oncology and the next steps for the REL-1017 program in depression as the primary drivers of value.
For a detailed history of the company's earnings and to view future revenue and EPS projections from analysts, you can review the historical earnings data and current analyst estimates and forecasts.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. Investing in equities, particularly clinical-stage biotechnology companies, carries a high level of risk, including the potential loss of principal. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.